Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2024-11-27 Capital/Financing Update
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
[기재정정]타인에대한담보제공결정
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical regarding a 'Decision to Provide Collateral to Others' (타인에 대한 담보제공 결정). It is a formal disclosure of a financial transaction involving the provision of collateral for a third party (an SPC). Since this does not fit into specific categories like M&A, dividends, or director dealings, and is a standard regulatory disclosure required by the Capital Markets Act, it falls under the 'Regulatory Filings' (RNS) category.
2024-11-27 Korean
[기재정정]타인에대한담보제공결정
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical regarding a 'Decision to Provide Collateral to Others' (타인에 대한 담보제공 결정). It is a formal disclosure of a corporate action involving financial guarantees and collateral, which does not fit into specific categories like earnings releases, dividends, or board changes. As it is a standard regulatory disclosure of a material event, it falls under the 'Regulatory Filings' category.
2024-11-22 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for JW Pharmaceutical (JW중외제약) for the period ending September 30, 2024. It contains detailed financial data, business operations, management analysis, and financial statements, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Report' (영업(잠정)실적) for JW Pharmaceutical for the third quarter of 2024. It provides key financial highlights such as revenue, operating profit, and net income, which are typical of an initial earnings announcement. Since it is a concise summary of financial results rather than a full quarterly report or a report publication announcement, it fits the definition of an Earnings Release (ER). Q3 2024
2024-11-06 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서) filed by the National Pension Service (국민연금공단) regarding their stake in JW Pharmaceutical (JW중외제약). This is a standard regulatory filing in South Korea (often referred to as a 5% rule filing) used to notify the market when an entity's shareholding crosses a significant threshold. It does not fit into categories like 10-K, Earnings Release, or M&A, and is best classified as a Major Shareholding Notification.
2024-10-07 Korean
타인에대한채무보증결정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from JW Pharmaceutical regarding a 'Decision on Debt Guarantee for Others' (타인에 대한 채무보증결정). It details a financial guarantee provided by the company for a subsidiary, including the amount, duration, and board approval details. As this is a specific regulatory disclosure regarding financial obligations and capital structure changes that does not fit into categories like M&A, dividends, or earnings releases, it is classified as a general Regulatory Filing (RNS).
2024-09-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.